مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

439
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

325
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

2

Information Journal Paper

Title

NONINVASIVE ASSESSMENT OF LIVER FIBROSIS WITH THE ASPARTATE TRANSAMINASE TO PLATELET RATIO INDEX (APRI): USEFULNESS IN PATIENTS WITH CHRONIC LIVER DISEASE

Pages

  103-107

Abstract

 Background: The ASPARTATE AMINOTRANSFERASES (AST) to platelet ratio index (APRI) may serve as a noninvasive marker to assess liver FIBROSIS.Objectives: To assess the diagnostic ability of the APRI for prediction of FIBROSIS in patients with CHRONIC HEPATITIS B (CHB), CHRONIC HEPATITIS C (CHC), and non-alcoholic FATTY LIVER disease (NAFLD).Patients and Methods: This retrospective study included 207 patients with CHB, 108 with CHC, and 140 patients with NAFLD. The APRI was calculated as (AST level/upper normal limit for AST)/platelet counts (109/L) ´ 100. The stage of liver FIBROSIS in patients with chronic viral hepatitis was graded using the METAVIR scale. The Kleiner system for grading FIBROSIS was used in patients with NAFLD. Results: Bivariate correlation analyses showed that the APRI was significantly associated with FIBROSIS scores in patients with CHC (p = 0.2634, p = 0.0059) and NAFLD (p = 0.2273, p = 0.0069), but not in those with CHB (p = 0.1005, p = 0.1495). Receiver operating characteristic (ROC) curves were used for assessing the ability of the APRI as a predictor of the absence or presence of liver FIBROSIS (fibrosis score of 0 vs FIBROSIS scores of 1-4). In patients with CHC, the APRI showed a sensitivity of 72.7% and a specificity of 62.4% for detection of FIBROSIS (p<0.01). In the NAFLD group, the APRI showed a sensitivity of 60.0% and specificity of 73.3% for detection of FIBROSIS (p<0.01). In patients with CHB, the APRI showed a sensitivity of 55.0% and a specificity of 75.4% for FIBROSIS (p=NS). Conclusions: The APRI shows an acceptable accuracy for the assessment of liver FIBROSIS in patients with CHC and NAFLD, but not in those with CHB.

Cites

References

  • No record.
  • Cite

    APA: Copy

    YILMAZ, Y., YONAL, O., KURT, R., BAYRAK, M., AKTAS, B., & OZDOGAN, O.. (2011). NONINVASIVE ASSESSMENT OF LIVER FIBROSIS WITH THE ASPARTATE TRANSAMINASE TO PLATELET RATIO INDEX (APRI): USEFULNESS IN PATIENTS WITH CHRONIC LIVER DISEASE. HEPATITIS MONTHLY, 11(2 (31)), 103-107. SID. https://sid.ir/paper/306347/en

    Vancouver: Copy

    YILMAZ Y., YONAL O., KURT R., BAYRAK M., AKTAS B., OZDOGAN O.. NONINVASIVE ASSESSMENT OF LIVER FIBROSIS WITH THE ASPARTATE TRANSAMINASE TO PLATELET RATIO INDEX (APRI): USEFULNESS IN PATIENTS WITH CHRONIC LIVER DISEASE. HEPATITIS MONTHLY[Internet]. 2011;11(2 (31)):103-107. Available from: https://sid.ir/paper/306347/en

    IEEE: Copy

    Y. YILMAZ, O. YONAL, R. KURT, M. BAYRAK, B. AKTAS, and O. OZDOGAN, “NONINVASIVE ASSESSMENT OF LIVER FIBROSIS WITH THE ASPARTATE TRANSAMINASE TO PLATELET RATIO INDEX (APRI): USEFULNESS IN PATIENTS WITH CHRONIC LIVER DISEASE,” HEPATITIS MONTHLY, vol. 11, no. 2 (31), pp. 103–107, 2011, [Online]. Available: https://sid.ir/paper/306347/en

    Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button